Hong Kong – September 27, 2026 -- Akeso, Inc. (9926.HK) has enrolled the first patient in COMPASSION-37, a global Phase III head-to-head trial testing its bispecific antibody cadonilimab against nivolumab as first-line treatment for HER2-negative advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.

New York – September 15, 2026 -- NYU Langone Health's Perlmutter Cancer Center has named Sean L. Berry, PhD, vice chair of physics and dosimetry in its Department of Radiation Oncology, recruiting a 20-year veteran of Memorial Sloan Kettering Cancer Center to lead treatment-planning quality and safety programs.